Hepatocellular Carcinoma Clinical Trial
Official title:
TACE Combined With Sorafenib and PD-1 mAb in the Treatment of BCLC B/C Hepatocellular Carcinoma: Single Arm, Single Center, Open Label Study
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that
ranks sixth in terms of incident cases, with an overall 5 years survival of 18%. Despite a
significant improvement in treatment strategy, the overall survival of HCC remains low due to
high recurrence, progressive liver dysfunction and the high fatality of the disease. Surgical
resection has been applied in a number of patients; however, surgery has been associated with
a high incidence of recurrence (approximately 70% within 5 years). TACE is generally applied
on intermediate-stage HCC. However, TACE is not satisfied with improving overall survival.
Therefore, there is an urgent need for effective treatment for these patients.
At present, the overall objective response rate (ORR) of single or sequential therapy is not
satisfied, and the over survival (OS) improvement is not ideal. Therefore, combined therapy
maybe the good choice for patients with advanced HCC.
This study focuses on the in-operable, BCLC-B/C HCC patients. Through the combination of
local therapy (TACE), anti-angiogenic therapy (Sorafenib), and immunotherapy (PD-1 monoclonal
antibody), it is expected to change the tumor microenvironment, restore the immune response,
strengthen the anti-tumor effect of various treatments, and improve the therapeutic efficacy
in patients with BCLC-B/C HCC.
This study is a single arm, single center, open label study. It is estimated that 60 patients
with BCLC-B/C HCC who can not receive radical resection will be enrolled.
The trial period of subjects includes screening period, treatment period and follow-up
period.
The drug treatment was 200 mg of PD-1 monoclonal antibody, intravenous infusion on the first
day, every 21 days as a treatment cycle; mesylate sorafenib, 400 mg, oral twice a day,
continuous oral; TACE, the lipiodol + blank microspheres and oxaliplatin (100 mg) +
epirubicin (50 mg) were injected into the hepatic artery by routine procedure, repeated every
4-6 weeks, and administered for according to the physician in charge, TACE treatment cycles.
Treatment continues until the disease progresses, intolerable toxicity occurs, new anti-tumor
treatment is started, informed consent is withdrawn, follow-up is lost, death occurs or
treatment termination is required。 Screening will be performed between days - 21 and - 4.
Informed consent was signed up to 4 weeks prior to the first day of cycle 1 before any
screening procedure or evaluation was performed and the trial was fully explained to each
subject.
Baseline evaluation results must be collected prior to the first trial drug administration
(day 1 of cycle 1). Baseline assessments may be performed between days - 3 and - 1 or on day
1 of cycle 1. If performed within 3 days before the first day of cycle 1, the screening
results can be used as baseline results.
The tumor imaging was evaluated every 4-6 weeks since the first administration, and every 12
weeks (± 7 days) after 24 weeks. If there are clinical indications for disease progression,
tumor evaluation is more frequent. In the event of disease progression, unacceptable
toxicity, the subject's request to discontinue the trial or the subject's withdrawal of
consent, the subject will discontinue the trial treatment.
When the trial treatment is stopped, the treatment visit shall be stopped within 7 days after
the treatment is stopped in order to stop the treatment examination.
After the end of the treatment period (up to 2 years), subjects who can benefit from the
study drug will continue to study the treatment of the drug until disease progression,
intolerable adverse reactions, withdrawal of intensive care facility (ICF), other anti-tumor
treatment, loss of follow-up, death or termination of the study.
After the occurrence of a clinical event, if it is judged by the investigators that it should
be attributed to the progress of the disease and it is unlikely to recover even if the
patient continues to receive treatment, it can be evaluated as clinical deterioration. It is
up to the investigator to discuss and decide whether to continue or stop the treatment for
the subject and record in the study file.
At the end of the study, subjects who are still under study treatment can continue to receive
treatment through another extended study or other forms at the discretion of the investigator
if they are stable or relieved in the efficacy evaluation and can tolerate the adverse
reactions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |